Citations

Clear

2438 citation(s) found for "Ly, Amy".

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Zhang, Ting , Bouchonville, Kelly J. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

No container title available | January 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.1 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Temesgen, Zoey B , Stroka, Deborah , Largiadèr, Carlo R , Offer, Steven M , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

eLife | January 10, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.94075 | PMID 38686795 Get It

Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Life or Limb - Why Not Both? Pediatric Lower Extremity Reconstruction with Concomitant Gustilo Class 3 Fractures
Upadhyaya, Raghave M., Burns, Heather R. , Buchanan, Edward P. , Reece, Edward M., Perkins, Christopher, Pederson, William C., Xue, Amy S., Abu‐Ghname, Amjed , Perkins, Christopher M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 8, 2024 | Volume: 12 | Issue: 1S1 | Pages: 21-21

10.1097/01.gox.0001005948.38773.b9 Get It

Stable thyroid cancer in a patient with thoracic aortic aneurysm and MYH11 variation
Fatourechi, Vahab , Swanson, Amy A. , Lee, Robert A.

Mayo Clinic

Endocrinology, Diabetes & Metabolism Case Reports | January 8, 2024 | Volume: 2024 | Issue: 1 | Pages: No page available

10.1530/edm-23-0088 | PMID 38189791 Get It

Summary We report the case of a male patient with papillary thyroid cancer, familial thoracic aortic aneurysm and dissection, and a variation in the MYH11 gene. Because of considerable tumor bulk in the neck that was not resectable, the patient underwent partial resection at age 14 years. Since then, the patient has received only suppressive thyroid hormone therapy. He is now 71 years old, which is 57 years after the initial resection. The patient received care at our institution from July 2009 to August 2019, during which we documented the stability of multiple calcified masses in the neck. Follow-up examinations at another institution from September 2019 to April 2023 also confirmed the stability of the masses. The underlying cause of this unusually long indolent course of the disease is unclear. Whether extensive tumor calcifications or the MYH11 sequence variation contributed to the disease course is also uncertain. Learning points Papillary thyroid cancer with neck metastases may, in some cases, be stable and remain asymptomatic for decades. If locoregional stability of papillary thyroid cancer is documented for many years, observation may be preferable to extensive neck surgery in selected cases. This is the first report of an MYH11 gene alteration and thoracic aortic aneurysm in a patient with papillary thyroid cancer with indolent neck metastases. Future studies of MYH11 gene alterations in thyroid carcinoma are needed.
Macrophage RAGE activation is proinflammatory in NASH
Parthasarathy, Gopanandan , Mauer, Amy S. , Golla, Naresh, Daniel, P. Vineeth , Kim, Lily H. , Sidhu, Guneet , rd, George W. Marek, Loeuillard, Emilien , Krishnan, Anuradha, Lee, Hyun Se Kim , Marek, George W, Kim Lee, Hyun Se , Daniel, P Vineeth , Pavelko, Kevin D. , Charlton, Michael , Hirsova, Petra , Ilyas, Sumera I. , Malhi, Harmeet

Mayo Clinic

JCI Insight | January 4, 2024 | Volume: 9 | Issue: 3 | Pages: No page available

10.1172/jci.insight.169138 | PMID 38175729 Get It

Intrahepatic macrophages in nonalcoholic steatohepatitis (NASH) are heterogenous and include proinflammatory recruited monocyte-derived macrophages. The receptor for advanced glycation endproducts (RAGE) is expressed on macrophages and can be activated by damage associated molecular patterns (DAMPs) upregulated in NASH, yet the role of macrophage-specific RAGE signaling in NASH is unclear. Therefore, we hypothesized that RAGE-expressing macrophages are proinflammatory and mediate liver inflammation in NASH. Compared with healthy controls, RAGE expression was increased in liver biopsies from patients with NASH. In a high-fat, -fructose, and -cholesterol–induced (FFC)-induced murine model of NASH, RAGE expression was increased, specifically on recruited macrophages. FFC mice that received a pharmacological inhibitor of RAGE (TTP488), and myeloid-specific RAGE KO mice (RAGE-MKO) had attenuated liver injury associated with a reduced accumulation of RAGE + recruited macrophages. Transcriptomics analysis suggested that pathways of macrophage and T cell activation were upregulated by FFC diet, inhibited by TTP488 treatment, and reduced in RAGE-MKO mice. Correspondingly, the secretome of ligand-stimulated BM-derived macrophages from RAGE-MKO mice had an attenuated capacity to activate CD8 + T cells. Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH.
Virology—the path forward
Grönvall, Gigi Kwik , Lowen, Anice C. , Goodrum, Felicia , Alwine, James C. , Andersen, Kristian G. , Anthony, Simon J. , Baines, Joel D. , Banerjee, Arinjay , Broadbent, Andrew J. , Brooke, Christopher B. , Campos, Samuel K. , Caposio, Patrizia , Chan, Gary C. , Collins-McMillen, Donna , Connell, Nancy , Damania, Blossom , Daugherty, Matthew D. , Dermody, Terence S. , Galloway, Denise A. , Hartman, Amy L. , Hogue, Brenda G. , Jung, Jae U. , Karst, Stephanie M. , Laimins, Lou, Landais, Igor, Lindenbach, Brett D. , Luftig, Micah A. , Mehle, Andrew , Moscona, Anne , Münger, Karl , Nikolich‐Žugich, Janko , Popescu, Saskia , Racaniello, Vincent R. , Rice, Charles M. , Runstadler, Jonathan A. , Sapp, Martin , Scott, Rona S. , Streblow, Daniel N. , Doorslaer, Koenraad Van , White, Elizabeth , White, Timothy M. , Worobey, Michael , Yamaoka, Satoko , Rasmussen, Angela L , Gronvall, Gigi K , Lowen, Anice C , Goodrum, Felicia , Baines, Joel , Banerjee, Arinjay , Broadbent, Andrew J , Brooke, Christopher B , Campos, Samuel K , Caposio, Patrizia , Casadevall, Arturo , Chan, Gary C , Cliffe, Anna R , Damania, Blossom , Dermody, Terence S , DiMaio, Daniel , Duprex, W Paul , Greninger, Alexander L , Hartman, Amy L , Horner, Stacy M , Jung, Jae U , Kamil, Jeremy P , Laimins, Lou , Lakdawala, Seema S , Letko, Michael , Liu, Shan-Lu , Luftig, Micah , McFadden, Grant , Mehle, Andrew , Moscona, Anne , Munger, Joshua , Murphy, Eain , O'Connor, Christine M , Pekosz, Andrew , Permar, Sallie R , Pfeiffer, Julie K , Purdy, John G , Runstadler, Jonathan A , Sapp, Martin J , Scott, Rona S , Smith, Gregory A , Tibbetts, Scott A , Toth, Zsolt , Weiss, Susan R , White, Elizabeth A , Wobus, Christiane E , Yurochko, Andrew , Nikolich, Janko Z , Casadevall, Arturo , Debbink, Kari M. , Duprex, W. Paul , Emerman, Michael , Garry, Robert F. , Goldstein, Stephen A. , Greninger, Alexander L. , Hotez, Peter Jay , Morrison, Juliet , Mühlberger, Elke , Neufeldt, Christopher John , O’Connor, Christine M. , Permar, Sallie R. , Sorrell, Erin M. , Speranza, Emily E. , Wobus, Christiane E.

Mayo Clinic

Journal of Virology | January 3, 2024 | Volume: 98 | Issue: 1 | Pages: No page available

10.1128/jvi.01791-23 | PMID 38168672 Get It

ABSTRACT In the United States (US), biosafety and biosecurity oversight of research on viruses is being reappraised. Safety in virology research is paramount and oversight frameworks should be reviewed periodically. Changes should be made with care, however, to avoid impeding science that is essential for rapidly reducing and responding to pandemic threats as well as addressing more common challenges caused by infectious diseases. Decades of research uniquely positioned the US to be able to respond to the COVID-19 crisis with astounding speed, delivering life-saving vaccines within a year of identifying the virus. We should embolden and empower this strength, which is a vital part of protecting the health, economy, and security of US citizens. Herein, we offer our perspectives on priorities for revised rules governing virology research in the US.
Quality improvement initiative to improve communication domains of patient satisfaction in a regional community hospital with Six Sigma methodology
Carsten, Brittan F, Bhandari, Pawan , Fortney, Benjamin J, Wilmes, Danielle S, Nelson, Cassandra M, Brien, Amy L, Walth, Rachel M, Anil, Gokhan

Mayo Clinic

BMJ Open Quality | December 30, 2023 | Volume: 12 | Issue: 4 | Pages: e002306

10.1136/bmjoq-2023-002306 | PMID 38160018 Get It

Background Communication gaps, whether incomplete or fragmented communication, have been the cause of many disasters in human civilisation. Coordination of healthcare is directly related to proper communication and handoffs among multidisciplinary teams throughout multiple shifts during a patient’s hospitalisation. Local problem Patient surveys and direct patient feedback at Mayo Clinic Health System in Mankato, Minnesota, indicated that patient communication with physicians and nurses had declined in 2017 and 2018. Viewing this as an opportunity for improvement, our leadership initiated several changes to increase physician and nurse communication with patients, which resulted in no notable improvements. Methods A systematic quality improvement approach was implemented by using Six Sigma methodology. Stakeholders from multidisciplinary teams were assembled as the project team. The five steps of Six Sigma methodology (Define, Measure, Analyse, Improve and Control) were followed to create a quality improvement intervention. Intervention We developed a standardised and easy-to-use bedside team rounding tool to improve patient communication with physicians and nurses. Results Postintervention patient satisfaction top-box scores exceeded target improvements for both physician (from 78.5% to 82.0%, p<0.01) and nurse (from 80.5% to 83.1%, p=0.04) communication domains. Physicians had a 33-point increase in percentile rank (from 41st to 74th percentile rank), and nurses had a 25-point increase in percentile rank (from 59th to 84th percentile rank). This increase in communication ranked our institution at the top of national benchmark organisations. Conclusions Overwhelmingly positive patient feedback was achieved, and postintervention employee satisfaction was primarily positive when compared with preintervention satisfaction.
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Kyalwazi, Beverly , Campbell, Michael J. , Chien, A. Jo , Forero-Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Haley, Barbara , Clark, Amy S. , Nanda, Rita , Yung, Rachel L. , Tripathy, Debasish , Edmiston, Kristen K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Lu, Ruixiao , Symmans, W. Fraser , Yee, Douglas , Veer, Laura van ‘t , Esserman, Laura J. , Olopade, Olufunmilayo I. , Tripathy, Debu , Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , Yau, Christina , Yoshimatsu, Toshio F. , Wallace, Anne M. , Pusztai, Lajos , Blaes, Anne , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , DeMichele, Angela , Veer, Laura J. van’t

Mayo Clinic

JAMA Network Open | December 28, 2023 | Volume: 6 | Issue: 12 | Pages: e2349646

10.1001/jamanetworkopen.2023.49646 | PMID 38153734 Get It

ImportanceThere has been little consideration of genomic risk of recurrence by breast cancer subtype despite evidence of racial disparities in breast cancer outcomes.ObjectiveTo evaluate associations between clinical trial end points, namely pathologic complete response (pCR) and distant recurrence–free survival (DRFS), and race and examine whether gene expression signatures are associated with outcomes by race.Design, Setting, and ParticipantsThis retrospective cohort study used data from the Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 (I-SPY 2) multicenter clinical trial of neoadjuvant chemotherapy with novel agents and combinations for patients with previously untreated stage II/III breast cancer. Analyses were conducted of associations between race and short- and long-term outcomes, overall and by receptor subtypes, and their association with 28 expression biomarkers. The trial enrolled 990 female patients between March 30, 2010, and November 5, 2016, with a primary tumor size of 2.5 cm or greater and clinical or molecular high risk based on MammaPrint or hormone receptor (HR)-negative/ERBB2 (formerly HER2 or HER2/neu)–positive subtyping across 9 arms. This data analysis was performed between June 10, 2021, and October 20, 2022.ExposureRace, tumor receptor subtypes, and genomic biomarker expression of early breast cancer.Main Outcomes and MeasuresThe primary outcomes were pCR and DRFS assessed by race, overall, and by tumor subtype using logistic regression and Cox proportional hazards regression models. The interaction between 28 expression biomarkers and race, considering pCR and DRFS overall and within subtypes, was also evaluated.ResultsThe analytic sample included 974 participants (excluding 16 self-reporting as American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or multiple races due to small sample sizes), including 68 Asian (7%), 120 Black (12%), and 786 White (81%) patients. Median (range) age at diagnosis was 47 (25-71) years for Asian, 49 (25-77) for Black, and 49 (23-73) years for White patients. The pCR rates were 32% (n = 22) for Asian, 30% for Black (n = 36), and 32% for White (n = 255) patients (P = .87). Black patients with HR-positive/ERBB2-negative tumors not achieving pCR had significantly worse DRFS than their White counterparts (hazard ratio, 2.28; 95% CI, 1.24-4.21; P = .01), with 5-year DRFS rates of 55% (n = 32) and 77% (n = 247), respectively. Black patients with HR-positive/ERBB2-negative tumors, compared with White patients, had higher expression of an interferon signature (mean [SD], 0.39 [0.87] and −0.10 [0.99]; P = .007) and, compared with Asian patients, had a higher mitotic score (mean [SD], 0.07 [1.08] and −0.69 [1.06]; P = .01) and lower estrogen receptor/progesterone receptor signature (mean [SD], 0.31 [0.90] and 1.08 [0.95]; P = .008). A transforming growth factor β signature had a significant association with race relative to pCR and DRFS, with a higher signature associated with lower pCR and worse DRFS outcomes among Black patients only.Conclusions and RelevanceThe findings show that women with early high-risk breast cancer who achieve pCR have similarly good outcomes regardless of race, but Black women with HR-positive/ERBB2-negative tumors without pCR may have worse DRFS than White women, highlighting the need to develop and test novel biomarker-informed therapies in diverse populations.
Unobtrusive In‐Home Digital Monitoring of Frontotemporal Dementia: Feasibility and Adherence
Wise, Amy B. , Rodrigues, Nathaniel , Gothard, Sarah , Heuer, Hilary W. , Forsberg, Leah K. , Chávez, Diana , Holiday, Kelsey A., Mendez, Mario F. , Boxer, Adam L. , Rosen, Howard J. , Staffaroni, Adam M. , Paolillo, Emily W. , Beattie, Zachary , Wu, Chao‐Yi , Boeve, Bradley F. , Kaye, Jeffrey

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.071655 Get It

AbstractBackgroundFrontotemporal Dementia (FTD) patients are geographically dispersed and often have behavioral and/or motor deficits that limit access to in‐person clinical trials and research. To address these participation barriers, we investigated the feasibility of installing in‐home sensor technologies to remotely assess everyday functioning in FTD.MethodWe aimed to recruit 20 FTD participants with a variety of clinical syndromes, including behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), corticobasal syndrome (CBS), and progressive supranuclear palsy (PSP). We also aimed to enroll a study partner for each participant that lived in the same home to serve as a control. The Collaborative Aging Research Using Technology (CART) platform was installed in participants’ homes to collect continuous data for up to two years, using motion sensors, physiological monitoring devices (e.g., scales, sleep sensors), electronic pillboxes, and wearable actigraphs. Computer use and driving patterns were also tracked. Technology was installed either via a study coordinator visit or remotely through video and written instructions, based on schedule and logistics. Participants were asked to complete a weekly Qualtrics survey about time away from home, visitors, and health changes.ResultOf the 159 UCSF participants available for recruitment through ALLFTD and other FTD projects, 28% (N = 45) met inclusion criteria. Of those 45, ten were ineligible due to advanced disease severity or relocation to an assisted living facility. A third (36%, N = 17) declined due to overwhelmed study partners (N = 3), declined any subproject participation (N = 7), sensitivity to participant’s diagnosis (N = 2), or lack of response (N = 5). Two additional participants were recruited through UCLA’s ALLFTD cohort. The platform has been installed in 19 homes (bvFTD: n = 10; PPA: n = 5; CBS/PSP: n = 4). Two homes discontinued due to death or relocation to assisted living facility. Mean data collection is 360 days (max = 527). Of 103 reported technological issues, 92% were resolved without additional home visits, either by phone or email. Participants completed 65% of weekly health questionnaires.ConclusionsAlthough there were some recruitment and retention challenges, these findings generally provide preliminary support for the feasibility and sustainability of conducting comprehensive in‐home passive data research in FTD.
The relationship of intraindividual variability on mobile cognitive testing with age and frontotemporal dementia disease severity
Clark, Annie L , Wise, Amy B. , Dhanam, Sreya, Taylor, Jack C. , Heuer, Hilary W. , Kramer, Joel H. , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Dhanam, Sreya , Paolillo, Emily W. , Hassenstab, Jason , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.080641 Get It

AbstractBackgroundThere has been a rise in remote cognitive testing for neurodegenerative diseases. The ALLFTD Mobile App is designed to capture clinical features of frontotemporal dementia (FTD) through repeated remote assessment on smartphones. This is a departure from traditional neuropsychological practice in which a single examiner‐led assessment occurs in a controlled setting. When participants complete tasks on their own, those with greater disease severity may be more variable in their performance for a variety of reasons (e.g. greater distractibility, less engagement). Here we study whether intraindividual cognitive variability (IIV) is associated with older age and increasing disease severity.MethodParticipants were 279 (mean age = 54.9) healthy controls and participants with sporadic FTD or from familial FTD kindreds with a range of disease severities based on FTLD Clinical Dementia Rating scale (CDR®+NACC‐FTLD Global) scores: 0 (n = 132), 0.5 (n = 54), and ≥1 (n = 47). Participants completed three cognitive tasks at least two times across twelve days. Measures included an adaptive memory task and gamified versions of Flanker and Go/no‐go tasks. IIV was operationalized as the standard deviation in performance on each task. Regression analyses investigated the relationship of IIV with CDR®+NACC‐FTLD group, and with age in those without symptoms. Education and gender were included as covariates in all analyses.ResultGreater disease severity (CDR®+NACC‐FTLD) was associated with greater variability on Flanker (p<.001) and Go/No‐go (p = .02) tasks; a positive but non‐significant association was seen with memory testing (p = .16). Post‐hoc comparisons found that those with CDR®+NACC‐FTLD of 0.5 had significantly more IIV on the Flanker task (𝛃 = .39, p = .004) than those with CDR®+NACC‐FTLD’s of 0. Moreover, those with a CDR®+NACC‐FTLD ≥1 had significantly greater IIV on the Flanker (𝛃 = .85, p<.001) and Go/No‐go tasks (𝛃 = .51, p = .007) than those with a CDR®+NACC‐FTLD of 0. In those without symptoms (CDR®+NACC‐FTLD = 0), age was associated with increased IIV on the Flanker (𝛃 = .27, p<.001) and Go/no‐go (𝛃 = .23, p<.001) tasks.ConclusionIncreased IIV, particularly on processing speed/executive functioning tasks, was associated with greater age and greater functional impairment, even in the mildest stages. Future investigations exploring predictors of IIV and the prognostic value of IIV are warranted.